Full Press Release Details
| Media Contact: | Lisa Weser, Trailblaze | |
| lisa@trailblaze.co | ||
| +1 (314) 625-4633 |
Arcadia Biosciences Announces Third-Quarter 2019 Financial Results and Business Highlights
-- Company announces plans for hemp seed sales, highlights first GoodWheatTM sales commitments and USDA approval of HB4 soybeans --
DAVIS, Calif. (Nov. 6, 2019) - Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional content of crops, today released its financial results and business highlights for the third quarter and first nine months of 2019.
"We achieved important progress during the third quarter in both product commercialization and continuing research and development in each of our three strategic crop categories - hemp, wheat and soy," said Matthew Plavan, president and CEO. "We continue to lay the foundations for rapid revenue growth, across multiple product lines in 2020 and beyond, with notable acceleration of our hemp genetic innovations to enhance the enterprise value of our growing germplasm estate."
Last week, the United States Department of Agriculture (USDA) issued their interim final rule for hemp production. This long-awaited guidance further codifies the contents of the 2018 Farm Bill and is the next step forward for the expansion of legal hemp cultivation in the United States.
With this new ruling, states must mandate procedures for testing hemp crops for tetrahydrocannabinol (THC), the psychoactive compound, and disposing of "hot" crops that exceed 0.3% THC.
"Now that the THC content of U.S. hemp crops will be closely monitored by the USDA, the hemp research we have underway in Hawaii and California is more valuable than ever," said Plavan. "We are bringing modern breeding science and genomics technology to develop high-quality non-GM hemp varieties with improved uniformity, stability, resiliency and yield, enabling farmers to maximize the value and profitability of this newly-legal crop."
Plavan continued, "As an agricultural technology company accustomed to working within USDA and the U.S. Food and Drug Administration (FDA) regulated sectors, we welcome these rules, which enable us to move forward with our plans for both cannabidiol (CBD) production and hemp germplasm improvement."
Earlier this year, Arcadia gave guidance for significant revenue generation over the next two years, projected to exceed $10 million in 2020 and $30 million in 2021. Based upon this revenue growth, the company expects to generate net cash from operating activity by mid to late 2021, with sustained profitability thereafter.
"We are working hard every day to bring consumers new and improved healthy food options, while maintaining a single-minded focus: profitable growth," said Plavan.
Recent Operating and Business Highlights
Arcadia Biosciences, Inc.
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||
| 2019 | 2018 | Favorable / (Unfavorable) | 2019 | 2018 | Favorable / (Unfavorable) | ||||||||||||||||||||||||||||
| $ | % | $ | % | ||||||||||||||||||||||||||||||
| Total revenues | 392 | 370 | 22 | (6 | )% | 753 | 1,020 | (267 | ) | (26 | )% | ||||||||||||||||||||||
| Total operating expenses | 6,585 | 4,469 | (2,116 | ) | (47 | )% | 16,145 | 13,536 | (2,609 | ) | (19 | )% | |||||||||||||||||||||
| Loss from operations | (6,193 | ) | (4,099 | ) | (2,094 | ) | (51 | )% | (15,392 | ) | (12,516 | ) | (2,876 | ) | (23 | )% | |||||||||||||||||
| Net (Loss) income | (14,187 | ) | 4,450 | (18,637 | ) | (419 | )% | (22,562 | ) | (12,834 | ) | (9,728 | ) | (76 | )% |
In the third quarter of 2019, revenues were $392,000, compared to revenues of $370,000 in the third quarter of 2018 and first nine months 2019 revenues were $753,000, compared to $1.0 million during the same period of 2018. The $267,000 decrease in the nine-month period was largely the result of the wind down in government grant and contract research activity. Arcadia expects product and trait revenues from hemp and wheat to start replacing government grant and contract research revenues in the coming months.
Operating expenses in the third quarter and first nine months of 2019 were $6.6 million and $16.1 million, compared to $4.5 million and $13.5 million in the third quarter and first nine months of 2018. Cost of product revenues were $53,000 more in the third quarter of 2019 compared to the third quarter of 2018 due to higher GLA sales. There was a GLA inventory write-down in 2018 that was not present in 2019, which generated the $107,000 decrease in cost of product revenues from the first nine months of 2019 compared to the first nine months of 2018. Research and development (R&D) spending increased by $597,000 and $863,000 in the third quarter and first nine months of 2019 compared to the the same periods in 2018, primarily due to additional soybean pre-commercial activities, higher employee expenses and hemp related costs. General and administrative (SG&A) expenses for the third quarter of 2019 were $1.5 million and $1.9 million higher than in the third quarter and first nine months of 2018, mainly the result of additional employee-related expenses, consulting fees and stock compensation expense, as well as increased marketing and public relations activities. Third quarter 2019 stock compensation expense included $662,000 of one-time charges for the accelerated vesting of a consultant's performance-based warrants and the modification of our former CEO's stock options in connection with his separation.
Net loss for the third quarter of 2019 was $14.2 million, or ($2.04) per share, a 419 percent decrease from the $4.5 million net income recognized in the third quarter of 2018. Net loss for the first nine months of 2019 was $22.6 million, or ($4.01) per share, compared to the net loss of $12.8 million for the first nine months of 2018. The difference for both periods was largely due to the change in the fair value of the common stock warrant and common stock adjustment feature liabilities, which is driven by the number of common stock warrants outstanding, as well as the change in the stock price. Net loss for the third quarter and first nine months of 2019 included non-cash expense of $7.8 million and $6.8 million for the change in the fair value of common stock warrant and common stock adjustment feature liabilities, as compared to $8.4 million and $6.0 million of non-cash income recorded in the third quarter and first nine months of 2018.
Conference Call and Webcast
The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, November 6, to discuss third-quarter and first nine months financial results and key strategic achievements.
Interested participants can join the conference call using the following numbers:
| U.S. Toll-Free Dial-In: | +1-844-243-4690 |
| International Dial-In: | +1-225-283-0138 |
| Passcode: | 3489473 |
A live webcast of the conference call will be available on the "Investors" section of Arcadia's website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.
About Arcadia Biosciences, Inc.
Arcadia Biosciences (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia's GoodWheat branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company's agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. Arcadia Specialty Genomics is a business unit within Arcadia Biosciences dedicated to the optimization and standardization of cannabis plant content, quality, resiliency and yield. For more information, visit www.arcadiabio.com.
Safe Harbor Statement
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to components of the company's long-term financial success and ongoing plans; the company's traits, commercial products, and collaborations; and the company's ability to manage the regulatory processes for its traits and commercial products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's and its partners' ability to develop commercial products incorporating its traits and to complete the regulatory review process for such products; the company's compliance with laws and regulations that impact the company's business, and changes to such laws and regulations; and the company's future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled "Risk Factors" and additional information set forth in its Form 10-K for the year ended December 31, 2018. These documents are available on the SEC Filings section of the Investor Relations pages of the company's website at www.arcadiabio.com. All information provided in this release and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.
Arcadia Biosciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| September 30, 2019 | December 31, 2018 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 20,541 | $ | 11,998 | ||||
| Short-term investments | 10,355 | 9,825 | ||||||
| Accounts receivable | 127 | 165 | ||||||
| Unbilled revenue | - | 3 | ||||||
| Inventories - current | 1,843 | 181 | ||||||
| Prepaid expenses and other current assets | 740 | 704 | ||||||
| Total current assets | 33,606 | 22,876 | ||||||
| Property and equipment, net | 1,283 | 395 | ||||||
| Right of use asset | 1,911 | - | ||||||
| Inventories - noncurrent | 495 | 746 | ||||||
| Other noncurrent assets | 7 | 7 | ||||||
| Total assets | $ | 37,302 | $ | 24,024 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 5,016 | $ | 2,645 | ||||
| Amounts due to related parties | 28 | 29 | ||||||
| Notes payable - current | 24 | - | ||||||
| Unearned revenue - current | 80 | 96 | ||||||
| Operating lease liability - current | 609 | - | ||||||
| Other current liabilities | 266 | 284 | ||||||
| Total current liabilities | 6,023 | 3,054 | ||||||
| Notes payable - noncurrent | 113 | - | ||||||
| Operating lease liability - noncurrent | 1,450 | - | ||||||
| Common stock warrant liabilities | 12,483 | 5,083 | ||||||
| Other noncurrent liabilities | 3,000 | 3,072 | ||||||
| Total liabilities | 23,069 | 11,209 | ||||||
| Stockholders' equity: | ||||||||
| Common stock, $0.001 par value-150,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 8,646,149 and 4,774,919 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively | 49 | 45 | ||||||
| Additional paid-in capital | 214,423 | 191,136 | ||||||
| Accumulated deficit | (200,928 | ) | (178,366 | ) | ||||
| Total Arcadia Biosciences stockholders' equity | 13,544 | 12,815 | ||||||
| Non-controlling interest | 689 | - | ||||||
| Total stockholders' equity | 14,233 | 12,815 | ||||||
| Total liabilities and stockholders' equity | $ | 37,302 | $ | 24,024 |
Arcadia Biosciences, Inc.
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product | $ | 216 | $ | 144 | $ | 485 | $ | 393 | ||||||||
| License | 17 | 10 | 17 | 100 | ||||||||||||
| Contract research and government grants | 159 | 216 | 251 | 527 | ||||||||||||
| Total revenues | 392 | 370 | 753 | 1,020 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of product revenues | 177 | 124 | 324 | 431 | ||||||||||||
| Research and development | 1,931 | 1,334 | 5,387 | 4,524 | ||||||||||||
| Selling, general and administrative | 4,477 | 3,011 | 10,434 | 8,581 | ||||||||||||
| Total operating expenses | 6,585 | 4,469 | 16,145 | 13,536 | ||||||||||||
| Loss from operations | (6,193 | ) | (4,099 | ) | (15,392 | ) | (12,516 | ) | ||||||||
| Interest expense | (3 | ) | - | (3 | ) | - | ||||||||||
| Other income, net | 119 | 134 | 339 | 266 | ||||||||||||
| Initial loss on common stock warrant and common stock adjustment feature liabilities | - | - | - | (4,000 | ) | |||||||||||
| Change in fair value of common stock warrant and common stock adjustment feature liabilities | (7,777 | ) | 8,421 | (6,790 | ) | 5,986 | ||||||||||
| Offering costs | (336 | ) | (1 | ) | (702 | ) | (2,544 | ) | ||||||||
| Net (loss) income before income taxes | (14,190 | ) | 4,455 | (22,548 | ) | (12,808 | ) | |||||||||
| Income tax benefit (provision) | 3 | (5 | ) | (14 | ) | (26 | ) | |||||||||
| Net (loss) income | $ | (14,187 | ) | $ | 4,450 | $ | (22,562 | ) | $ | (12,834 | ) | |||||
| Net (loss) income per share: | ||||||||||||||||
| Basic and diluted | $ | (2.04 | ) | $ | 0.93 | $ | (4.03 | ) | $ | (3.74 | ) | |||||
| Weighted-average number of shares used in per share calculations: | ||||||||||||||||
| Basic and diluted | 6,942,612 | 4,774,732 | 5,596,545 | 3,427,799 | ||||||||||||
| Other comprehensive income, net of tax | ||||||||||||||||
| Unrealized losses on available-for-sale securities | (1 | ) | (2 | ) | - | (1 | ) | |||||||||
| Other comprehensive loss | (1 | ) | (2 | ) | - | (1 | ) | |||||||||
| Comprehensive (loss) income | $ | (14,188 | ) | $ | 4,448 | $ | (22,562 | ) | $ | (12,835 | ) |
Arcadia Biosciences, Inc.
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||||||||
| 2019 | 2018 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (22,562 | ) | $ | (12,834 | ) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||||||
| Initial loss on common stock warrant and common stock adjustment feature liabilities | - | 4,000 | ||||||
| Change in fair value of common stock warrant and common stock adjustment feature liabilities | 6,790 | (5,986 | ) | |||||
| Offering costs | 702 | 2,544 | ||||||
| Depreciation and amortization | 133 | 123 | ||||||
| Lease amortization | 530 | - | ||||||
| Gain (Loss) on disposal of equipment | 1 | (3 | ) | |||||
| Net amortization of investment premium | (121 | ) | (115 | ) | ||||
| Stock-based compensation | 1,870 | 998 | ||||||
| Changes in operating assets and liabilities: | - | - | ||||||
| Accounts receivable | 38 | 1,038 | ||||||
| Unbilled revenue | 3 | (164 | ) | |||||
| Inventories | (1,411 | ) | 301 | |||||
| Prepaid expenses and other current assets | (36 | ) | (334 | ) | ||||
| Accounts payable and accrued expenses | 2,425 | (142 | ) | |||||
| Amounts due to related parties | (1 | ) | (11 | ) | ||||
| Unearned revenue | (16 | ) | (351 | ) | ||||
| Other current liabilities | 3 | - | ||||||
| Operating lease payments | (534 | ) | - | |||||
| Net cash used in operating activities | (12,186 | ) | (10,936 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from sale of property and equipment | 1 | 10 | ||||||
| Purchases of property and equipment | (878 | ) | (89 | ) | ||||
| Purchases of investments | (18,458 | ) | (22,871 | ) | ||||
| Proceeds from sales and maturities of investments | 18,050 | 8,950 | ||||||
| Net cash used in investing activities | (1,285 | ) | (14,000 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock and warrants from June 2019 Offering | 7,500 | - | ||||||
| Payments of offering costs relating to June 2019 Offering | (663 | ) | - | |||||
| Proceeds from issuance of common stock and warrants from September 2019 Offering | 10,000 | - | ||||||
| Payments of offering costs relating to September 2019 Offering | (776 | ) | - | |||||
| Proceeds from issuance of common stock and warrants from Purchase Agreement | - | 10,000 | ||||||
| Payments of offering costs relating to Purchase Agreement | - | (1,308 | ) | |||||
| Proceeds from issuance of common stock and warrants from June 2018 Offering | - | 14,000 | ||||||
| Payments of offering costs relating to June 2018 Offering | (24 | ) | (1,181 | ) | ||||
| Principal payments on notes payable | (2 | ) | - | |||||
| Proceeds from exercise of warrants | 5,269 | - | ||||||
| Proceeds from exercise of stock options and ESPP purchases | 21 | 969 | ||||||
| Capital contributions received from non-controlling interest | 689 | - | ||||||
| Net cash provided by financing activities | 22,014 | 22,480 | ||||||
| Net increase (decrease) in cash and cash equivalents | 8,543 | (2,456 | ) | |||||
| Cash and cash equivalents - beginning of period | 11,998 | 9,125 | ||||||
| Cash and cash equivalents - end of period | $ | 20,541 | $ | 6,669 | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for income taxes | $ | 2 | $ | 24 | ||||
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Offering costs in accounts payable and accrued expenses at end of period | $ | 21 | $ | - | ||||
| Common stock warrants issued to placement agent and included in offering costs related to Purchase Agreement | $ | - | $ | 526 | ||||
| Common stock warrants issued to placement agent and included in offering costs related to June 2018 Offering | $ | - | $ | 239 | ||||
| Common stock warrants issued to placement agent and included in offering costs related to June 2019 Offering | $ | 86 | $ | - | ||||
| Common stock warrants issued to placement agent and included in offering costs related to September 2019 Offering | $ | 95 | $ | - | ||||
| Reclassification of common stock warrant liability balance with warrant exercises | $ | 7,016 | $ | - | ||||
| Reclassification of common stock adjustment feature liability balance | $ | - | $ | 8,378 | ||||
| Right of use assets obtained in exchange for new operating lease liabilities | $ | 2,328 | $ | - | ||||
| Fixed assets acquired with notes payable | $ | 139 | $ | - | ||||
| Purchases of fixed assets included in accounts payable and accrued expenses | $ | 6 | $ | - |